Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)

Trends in Pharmacological Sciences

Volumn 25, Issue 3, 2004, Pages 158-163

  O'Donnell, James M ^a   Zhang, Han Ting ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4,5 DIHYDRO 6 METHYL 5 OXO 4 PROPYL 1,2,4 TRIAZOLO[1,5 A]PYRIMIDINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIDEPRESSANT AGENT; CYCLIC AMP; CYCLIC GMP; DESIPRAMINE; DIZOCILPINE; FLUOXETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; EXPERIMENTAL MOUSE; FORCED SWIMMING TEST; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 1342264246     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.01.003     Document Type: Review

References (59)

1. Wachtel H. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berl.). 77:1982;309-316.
2. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 22:1983;267-272.
3. Zeller E. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 17:1984;188-190.
4. Nemoz G., et al. Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brain by the neurotrophic compound rolipram. Biochem. Pharmacol. 34:1985;2997-3000.
5. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs. 59:2000;193-212.
6. Marriott J.B., et al. Immunotherapeutic and antitumor potential of thalidomide analogues. Expert Opin. Biol. Ther. 1:2001;675-682.
7. Jacobitz S., et al. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. 50:1996;891-899.
8. Soderling J.H., Beavo J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 12:2000;174-179.
9. Francis S.H., et al. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65:2001;1-52.
10. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 69:2001;249-316.
11. Iona S., et al. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol. Pharmacol. 53:1998;23-32.
12. Cherry J.A., Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 407:1999;287-301.
13. Baillie G.S., et al. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 131:2000;811-819.
14. Mizokawa T., et al. The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats. Jpn. J. Pharmacol. 48:1988;357-364.
15. Overstreet D.H., et al. Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain. Pharmacol. Biochem. Behav. 34:1989;691-696.
16. Saccomano N.A., et al. Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2- imidazolidinones. J. Med. Chem. 34:1991;291-298.
17. O'Donnell J.M. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther. 264:1993;1168-1178.
18. Nakagawa S., et al. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci. 22:2002;3673-3682.
19. Santarelli L., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 301:2003;805-809.
20. Bonbon D., et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double-blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur. Arch. Psychiatry Neurol. Sci. 238:1988;2-6.
21. Laux G., et al. Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level. Pharmacopsychiatry. 21:1988;378-379.
22. Fleischhacker W.W., et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 26:1992;59-64.
23. Robichaud A., et al. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology. 38:1999;289-297.
24. Silvestre J.S., et al. Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats. Pharmacol. Biochem. Behav. 64:1999;1-5.
25. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17:(Suppl. 1):1997;2S-18S.
26. Ye Y., O'Donnell J.M. diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J. Neurochem. 66:1996;1894-1902.
27. Ye Y., et al. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J. Neurochem. 69:1997;2397-2404.
28. Perry S.J., et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 298:2002;834-836.
29. Baillie G.S., et al. Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc. Natl. Acad. Sci. U. S. A. 100:2003;940-945.
30. Takahashi M., et al. chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 19:1999;610-618.
31. Ye Y., et al. Effects of repeated antidepressant treatment on type 4A phosphodiesterase (PDE4A) in rat brain. J. Neurochem. 74:2000;1257-1262.
32. Miro X., et al. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology. 43:2002;1148-1157.
33. Sette C., Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271:1996;16526-16534.
34. Hoffmann R., et al. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 18:1999;893-903.
35. Le Jeune R., et al. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J. Biol. Chem. 277:2002;35980-35989.
36. Park J.Y., et al. Phosphodiesterase regulation is critical for the differentiation and pattern of gene expression in granulose cells of the ovarian follicle. Mol. Endocrinol. 17:2003;1117-1130.
37. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185:1990;1-10.
38. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263:1994;1-7.
39. Panconi E., et al. MK-801 and enantiomers: potential antidepressants or false positives in classical screening models. Pharmacol. Biochem. Behav. 46:1993;15-20.
40. Zhang H.T., et al. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology. 23:2000;198-204.
41. Suvarna N.U., O'Donnell J.M. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J. Pharmacol. Exp. Ther. 302:2002;249-256.
42. Conti M., et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 278:2003;5493-5496.
43. Zhang H.T., et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology. 27:2002;587-595.
44. Lamontagne S., et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. 920:2001;84-96.
45. Robichaud A., et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110:2002;1045-1052.
46. Schneider H.H., et al. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127:1986;105-115.
47. Souness J.E., Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell. Signal. 9:1997;227-236.
48. Schmiechen R., et al. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology (Berl.). 102:1990;17-20.
49. Barnette M.S., et al. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with high-affinity rolipram binding site. J. Pharmacol. Exp. Ther. 273:1995;1396-1402.
50. Barnette M.S., et al. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J. Pharmacol. Exp. Ther. 273:1995;674-679.
51. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39:1996;120-125.
52. 3H]rolipram. J. Pharmacol. Exp. Ther. 305:2003;565-572.
53. McPhee I., et al. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J. Biol. Chem. 274:1999;11796-11810.
54. Yarwood S.J., et al. the RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5. J. Biol. Chem. 274:1999;14909-14917.
55. Dodge K.L., et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J. 20:2001;1921-1930.
56. Houslay M.D., Adams D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signaling cross-talk, desensitization and compartmentalization. Biochem. J. 370:2003;1-18.
57. Zhao Y., et al. Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. J. Pharmacol. Exp. Ther. 307:2003;246-253.
58. Xu R.X., et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. 288:2000;1822-1825.
59. Sung B.J., et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 425:2003;98-102.